Deuterated Water Labeling in Ibrutinib-Treated Patients With Cll: Leukemia Cell Kinetics Correlate With IGHV, ZAP-70, and MRD

Authors

Ekaterina Kim
Shih-Shih Chen
Mariela Sivina
Hyunsoo Hwang
Xuelin Huang
Alessandra Ferrajoli
Nitin Jain
William G Wierda
Dominik Wodarz
Nicholas Chiorazzi
Jan A Burger

Language

English

Publication Date

12-19-2024

Journal

Blood

DOI

10.1182/blood.2024025683

PMID

39441901

PMCID

PMC11830972

PubMedCentral® Posted Date

10-28-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Deuterated (“heavy”) water labeling in patients with chronic lymphocytic leukemia (CLL) demonstrates that IGHV unmutated and ZAP-70+ patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease levels with long-term ibrutinib treatment. This trial was registered at www.clinicaltrials.gov as #NCT01752426.

Keywords

Humans, Adenine, Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, ZAP-70 Protein-Tyrosine Kinase, Pyrazoles, Pyrimidines, Neoplasm, Residual, Male, Female, Immunoglobulin Heavy Chains, Aged, Middle Aged, Immunoglobulin Variable Region, Kinetics, Deuterium, Water

Published Open-Access

yes

Recommended Citation

Kim, Ekaterina; Chen, Shih-Shih; Sivina, Mariela; et al., "Deuterated Water Labeling in Ibrutinib-Treated Patients With Cll: Leukemia Cell Kinetics Correlate With IGHV, ZAP-70, and MRD" (2024). Faculty, Staff and Student Publications. 5402.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5402